Hemispherx participated in meeting with advocates for ME/CFS in Canada
Hemispherx Biopharma has announced that on Thursday, August 3 it participated in a meeting in Toronto, Canada with Canadian advocates for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, or ME/CFS. The meeting was lead by Millions Missing Canada and a Canadian physician representing Canadian patients with ME/CFS, in support of a collaborative effort to advance ME/CFS research and potential treatments in Canada. One year ago, Ampligen became the first drug therapy approved in the world for ME/CFS, receiving government approval from the Republic of Argentina. The plan is to use the existing Ampligen(R) new drug application database, to gain approval of Ampligen in severely debilitated ME/CFS patients in Canada.